A balancing act: Microbe versus muscle

Clinical Infectious Diseases

Volumn 49, Issue 2, 2009, Pages 181-183

  Cosgrove, Sara E ^a,c   Corey, G Ralph ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAM POSITIVE INFECTION; HUMAN; INFECTION RESISTANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; NOTE; PRIORITY JOURNAL; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MUSCLES;

EID: 67651091951     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600040     Document Type: Note

References (16)

1. Bush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D. In vitro postantibiotic effect of daptomycin (LY146032) against Entero- coccus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus au- reus strains. Antimicrob Agents Chemother 1989;33:1198-200.
2. Tally FP, DeBruin MF. Development of dap- tomycin for gram-positive infections. J Anti- microb Chemother 2000; 46:523-6.
3. Tedesco KL, Rybal MJ. Daptomycin. Pharmacotherapy 2004; 24:41-57.
4. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes dap- tomycin safety. Antimicrob Agents Chemo-ther 2000; 44:2948-53.
5. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of dap-tomycin for the treatment ofcomplicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81.
6. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bac- teremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
7. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006;35:207-11.
8. Cunha BA, Krol V, Kodali V. Methicillin-re-sistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmu- noglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin.Heart Lung 2008; 37:72-5.
9. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vanco- mycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49:2735-45.
10. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus au- reus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60:334-40.
11. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated en- docardial vegetations. Antimicrob Agents Chemother 2008; 52:3061-7.
12. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-23.
13. Benvenuto M, Benziger DP, Yankelev S, Vig- liani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-9.
14. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous dapto- mycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80 (in this issue).
15. Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005;46:233-41.
16. Livermore DM. Future directions with dap- tomycin. J Antimicrob Chemother 2008; 62(Suppl 3):iii41-9.